Biography

The Yi Laboratory has been working on tumor immunology and immunotherapy in multiple myeloma (MM) for 20 years. We were first to demonstrate the existence of idiotype-specific T cells in patients with MM and related disorders and that idiotype-specific cytotoxic T cells could lyse autologous primary myeloma cells.

Research Intrest

My group is generating novel monoclonal antibodies (mAbs) to treat patients with MM and other cancers. We discovered that mAbs specific to human b2-microglobulin (b2M) induce programmed death of MM and other hematological tumor cells. These mAbs were also active and therapeutic in vivo in xenograft mouse models. Our goal is to develop these and other mAbs as therapeutic agents to treat patients with MM and other malignancies.

List of Publications
Qian J, et al. Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma. Blood 2012;119:161-9.
Lu Y, et al. Th9 cells promote antitumor immune responses in vivo. J Clin Invest 2012;122:4160-71.
Zheng Y, et al. (2010) PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. Leukemia ;27:702-10.

Global Scientific Words in Medical Sciences